Menu
Sign In Pricing Add Podcast

BackTable Urology

Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay

288.166 - 309.6 Dr. Rana McKay

And then the antagonists have come around, which instead of, you know, working first to turn on the access before they turn it off, immediately suppress. And then, you know, now we've got androgen receptor pathway inhibitors. I mean, there's many of them out there that further suppress or block androgen signaling that have really entered into the landscape.

0
💬 0

Comments

There are no comments yet.

Log in to comment.